Expertise in
2
conditions

Dr. Marc S. Ernstoff

Oncology
Mary Hitchcock Memorial Hospital
1 Medical Center Dr, 
Lebanon, NH 
Expertise in
2
conditions
Mary Hitchcock Memorial Hospital
1 Medical Center Dr, 
Lebanon, NH 

Overview

Marc Ernstoff is an Oncologist practicing medicine in Lebanon, New Hampshire.

Dr. Ernstoff is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Melanoma, Renal Cell Carcinoma (RCC), Urothelial Cancer, and Neuroendocrine Tumor.

He is actively involved in clinical research, co-authoring 140 peer reviewed articles and participating in 10 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in NY

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Mary Hitchcock Memorial Hospital
1 Medical Center Dr, Lebanon, NH 03756

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase Ib/II Study of Propranolol With Fixed-Dose Pembrolizumab in Patients With Unresectable Stage III and Stage IV Melanoma
A Phase Ib/II Study of Propranolol With Fixed-Dose Pembrolizumab in Patients With Unresectable Stage III and Stage IV Melanoma
Enrollment Status: Suspended
Publish Date: July 15, 2026
Intervention Type: Drug, Other, Biological
Study Drugs: Pembrolizumab, Propranolol Hydrochloride
Study Phase: Phase 1/Phase 2
A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)
A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)
Enrollment Status: Active_not_recruiting
Publish Date: July 07, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial of Adjuvant Avelumab (Anti-PDL-1 Antibody) in Merkel Cell Carcinoma Patients With Lymph Node Metastases
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial of Adjuvant Avelumab (Anti-PDL-1 Antibody) in Merkel Cell Carcinoma Patients With Lymph Node Metastases
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Other, Drug
Study Drug: Avelumab
Study Phase: Phase 3
An Observational Pilot Study to Compare the Compliance With and Health Related Quality of Life During Therapy With Standard High-Dose Interferon Alfa (Intron A, HDI) Versus Pegylated Alfa-Interferon 2b (Sylatron, PEG IFN) in Patients With Surgically Resected Melanoma
An Observational Pilot Study to Compare the Compliance With and Health Related Quality of Life During Therapy With Standard High-Dose Interferon Alfa (Intron A, HDI) Versus Pegylated Alfa-Interferon 2b (Sylatron, PEG IFN) in Patients With Surgically Resected Melanoma
Enrollment Status: Completed
Publish Date: February 13, 2025
Phase I Study of MK-3475 (Pembrolizumab) in Patients With Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Phase I Study of MK-3475 (Pembrolizumab) in Patients With Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Enrollment Status: Completed
Publish Date: August 09, 2024
Intervention Type: Procedure, Drug, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 1
A Phase II Pilot Trial of an Indoleamine 2,3, Dioxygenase-1 (IDO1) Inhibitor (INCB024360) Plus a Multipeptide Melanoma Vaccine (MELITAC 12.1) in Patients With Advanced Melanoma
A Phase II Pilot Trial of an Indoleamine 2,3, Dioxygenase-1 (IDO1) Inhibitor (INCB024360) Plus a Multipeptide Melanoma Vaccine (MELITAC 12.1) in Patients With Advanced Melanoma
Enrollment Status: Completed
Publish Date: June 08, 2018
Intervention Type: Biological, Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

140 Total Publications

Retroelement Hypomethylation Links Hypoxia Signaling, Immune Phenotypes, and Survival in Clear Cell Renal Cell Carcinoma.
Retroelement Hypomethylation Links Hypoxia Signaling, Immune Phenotypes, and Survival in Clear Cell Renal Cell Carcinoma.
Journal: bioRxiv : the preprint server for biology
Published: May 18, 2026
Similar Doctors
Expertise in
13
conditions
Expertise in
13
conditions
Referral may be required

Mary Hitchcock Memorial Hospital

1 Medical Center Dr, 
Lebanon, NH 
 (0.1 miles away)
603-650-6345
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Konstantin Dragnev is an Oncologist practicing medicine in Lebanon, New Hampshire. Dr. Dragnev is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer.

Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Mary Hitchcock Memorial Hospital

1 Medical Center Dr, 
Lebanon, NH 
 (0.1 miles away)
603-650-4344
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Keisuke Shirai is an Oncologist practicing medicine in Lebanon, New Hampshire. Dr. Shirai is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Melanoma, Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and Head and Neck Squamous Cell Carcinoma (HNSCC).

Expertise in
9
conditions
Expertise in
9
conditions
Referral may be required

Mary Hitchcock Memorial Hospital

1 Medical Center Dr, 
Lebanon, NH 
 (0.1 miles away)
603-650-5529
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mary Chamberlin is an Oncologist practicing medicine in Lebanon, New Hampshire. Dr. Chamberlin is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Inflammatory Breast Cancer.

Frequently Asked Questions about Dr. Marc S. Ernstoff

How do I make an appointment with Dr. Marc S. Ernstoff?

You can book an appointment with Dr. Marc S. Ernstoff by calling their office at 603-650-5534. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Marc S. Ernstoff a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Marc S. Ernstoff is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Marc S. Ernstoff specialize in?

While Dr. Marc S. Ernstoff is a Oncology, they have specific expertise in Melanoma, Renal Cell Carcinoma (RCC), and Urothelial Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Marc S. Ernstoff participate in research or clinical trials?

Yes. Dr. Marc S. Ernstoff has published 140 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Marc S. Ernstoff's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Marc S. Ernstoff accept my insurance?

Dr. Marc S. Ernstoff accepts most major insurance plans, including Humana. We recommend calling the office directly at 603-650-5534 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ernstoff's expertise for a condition
ConditionClose
    View All 20 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile